AstraZeneca COVID-19 Vaccine: Will It Receive EU Approval? ... EMA to Announce Decision
If Approved, Third After Pfizer Vaccine and Moderna Vaccine
![[Image source=Yonhap News]](http://www.asiae.co.kr/news/img_view.htm?img=2021010414272998474_1609738049.jpg)
[Asia Economy Reporter Lim Cheol-young] The European Medicines Agency (EMA) is set to announce whether it will grant conditional marketing authorization for the AstraZeneca COVID-19 vaccine developed by the multinational pharmaceutical company AstraZeneca.
According to foreign media on the 29th (local time), the EMA is expected to recommend conditional marketing authorization for the AstraZeneca vaccine following an expert evaluation meeting. This vaccine was jointly developed by the multinational pharmaceutical company AstraZeneca and the University of Oxford in the UK. Conditional marketing authorization is a procedure designed to enable rapid response in emergency situations, allowing the medicine to be sold for one year across 27 member states.
Once the European Commission makes the final decision and the official approval process is completed, vaccinations can be administered within EU countries. This will be the third vaccine available for vaccination within the EU, following the vaccines developed by Pfizer and BioNTech, and Moderna. Previously, the EU approved the conditional marketing authorization for the Pfizer-BioNTech COVID-19 vaccine in December last year based on EMA’s recommendation, followed by the Moderna vaccine earlier this month.
Previously, the EU approved the conditional marketing authorization for the Pfizer-BioNTech COVID-19 vaccine in December last year based on EMA’s recommendation, followed by the Moderna vaccine earlier this month.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
The AstraZeneca vaccine has already received emergency approval in countries including the UK, India, Argentina, and Mexico. Although its average efficacy is lower compared to the Pfizer and Moderna vaccines, approval is being granted due to efforts by various countries to secure sufficient vaccine supplies. The average efficacy of AstraZeneca’s vaccine is 70.4%, which is lower than Pfizer’s (95.0%) and Moderna’s (94.5%).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
